It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences in 111 well-characterized patients. Besides prominent signatures of T-cell activation and prevalent clonal variants, we also identify novel hot-spots for CN variability, fusion molecules, alternative transcripts, and progression-associated dynamics. The overall lesional spectrum of T-PLL is mainly annotated to axes of DNA damage responses, T-cell receptor/cytokine signaling, and histone modulation. We formulate a multi-dimensional model of T-PLL pathogenesis centered around a unique combination of TCL1 overexpression with damaging ATM aberrations as initiating core lesions. The effects imposed by TCL1 cooperate with compromised ATM toward a leukemogenic phenotype of impaired DNA damage processing. Dysfunctional ATM appears inefficient in alleviating elevated redox burdens and telomere attrition and in evoking a p53-dependent apoptotic response to genotoxic insults. As non-genotoxic strategies, synergistic combinations of p53 reactivators and deacetylase inhibitors reinstate such cell death execution.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), UoC, Köln, Germany; CMMC, Center for Molecular Medicine University of Cologne (UoC), Köln, Germany
2 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), UoC, Köln, Germany; Senckenberg Institute of Pathology, Goethe-University, Frankfurt/M., Germany
3 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany
4 Hematology Research Unit Helsinki, Department of Medicine and Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital (HUCH), Helsinki, Finland
5 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), UoC, Köln, Germany
6 Institute of Animal Breeding and Genetics, University of Veterinary Medicine; Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna, Vienna, Austria
7 Department of Hematology, Oncology, and Stem Cell Transplantation, RWTH Aachen University Medical School, Aachen, Germany
8 Cologne Center for Genomics, UoC, Germany, Institute of Human Genetics, University of Cologne (UoC), Köln, Germany
9 Duke University Medical Center, Durham, NC, USA
10 MLL Munich Leukemia Laboratory, Munich, Germany
11 Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany
12 Department of Internal Medicine, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria
13 Department of Translational Genomics, UoC, Köln, Germany
14 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
15 Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Division of Pediatric Oncology, Department of Pediatrics, Columbia University Medical Center, Columbia University, New York, USA
16 INSERM U830, Institut Curie, PSL Research University, Paris, France
17 Senckenberg Institute of Pathology, Goethe-University, Frankfurt/M., Germany
18 Bioinformatics Core Facility, CECAD, UoC, Köln, Germany